Novartis Canada is pleased to announce that Scemblix® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario’s new ...
Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...
ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...
The FDA approved Bosulif for children aged 1 and older with newly diagnosed or resistant/intolerant chronic myelogenous leukemia. The Food and Drug Administration ...
Background: The initial results of imatinib in Ph-positive CML in chronic phase post IFN failure were positive with a median follow up times of 17 months. The major cytogenetic (CG) response rate (Ph ...
A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...
Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in ...
Articles published in this focus collection were selected from recent issues of Leukemia. They highlight new developments in our understanding and management of persons with CML. CML was the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback